CSIMarket


Revance Therapeutics Inc   (RVNC)
Other Ticker:  
 

Revance Therapeutics Inc

RVNC's Fundamental analysis








Looking into Revance Therapeutics Inc growth rates, revenue grew by 39.82 % in IV. Quarter 2023 from the same quarter a year ago.

Major Pharmaceutical Preparations industry recorded deterioration of revenues by

Revance Therapeutics Inc 's net income grew by 1.06 % in IV. Quarter 2023 year on year, above company average,

More on RVNC's Growth


Revance Therapeutics Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 19.86 in trailing twelve-month period.
Company
-
PE TTM   
Industry
283.76
PE TTM    
Company's Price to Sales ratio is at 2.52.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.8.


More on RVNC's Valuation
 
 Total Debt (Millions $) 429
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 672,529
 Net Income/Employee (TTM) $ -862
 Receivable Turnover (TTM) 10.95
 Tangible Book Value (Per Share $) -1.91

Revance Therapeutics Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 19.86 in trailing twelve-month period.
Company
-
PE TTM   
Industry
283.76
PE TTM    
Company's Price to Sales ratio is at 2.52.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.8.


More on RVNC's Valuation

  Market Capitalization (Millions $) 590
  Shares Outstanding (Millions) 85
  Employees 348
  Revenues (TTM) (Millions $) 234
  Net Income (TTM) (Millions $) 0
  Cash Flow (TTM) (Millions $) 30
  Capital Exp. (TTM) (Millions $) -7
  Total Debt (Millions $) 429
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 672,529
  Net Income/Employee(TTM) $ -862
  Receivable Turnover Ratio (TTM) 10.95
  Tangible Book Value (Per Share $) -1.91

  Market Capitalization (Millions $) 590
  Shares Outstanding (Millions) 85
  Employees 348
  Revenues (TTM) (Millions $) 234
  Net Income (TTM) (Millions $) 0
  Cash Flow (TTM) (Millions $) 30
  Capital Exp. (TTM) (Millions $) -7





  Ratio
   Capital Ratio (MRQ) 3.8
  Total Debt to Equity (MRQ) -
  Tangible Leverage Ratio (MRQ) -
  Asset Turnover Ratio (TTM) 0.47
  Inventory Turnover Ratio (TTM) 1.62





Revance Therapeutics Inc net profit margin of 182.11 % is currently ranking no. 4 in Major Pharmaceutical Preparations industry, ranking no. 5 in Healthcare sector and number 25 in S&P 500.

More on RVNC's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com